Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block

PHASE3RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

February 25, 2025

Study Completion Date

March 1, 2025

Conditions
Erector Spinae BlockDexmedetomidine
Interventions
DRUG

Dexmedetomidine Injection [Precedex]

Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia

DRUG

Bupivacaine Hydrochloride

.Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia

DRUG

Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)

Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.

Trial Locations (1)

81511

RECRUITING

Aswan University, Aswān

All Listed Sponsors
lead

Aswan University

OTHER